

# Lukas Hartl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8807797/publications.pdf>

Version: 2024-02-01

22  
papers

528  
citations

758635

12  
h-index

713013

21  
g-index

23  
all docs

23  
docs citations

23  
times ranked

250  
citing authors

#	ARTICLE	IF	CITATIONS
1	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1362-1373.e6.	2.4	39
2	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. <i>Hepatology</i> , 2022, 75, 610-622.	3.6	18
3	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	1.8	26
4	Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression. <i>Journal of Personalized Medicine</i> , 2022, 12, 239.	1.1	7
5	Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5693-5703.	1.1	5
6	The "Viennese epidemic" of acute HCV in the era of direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2022, 29, 385-394.	1.0	10
7	Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients. <i>Liver International</i> , 2022, 42, 1297-1307.	1.9	15
8	Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide" results of a real world study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 144-154.	1.9	46
9	Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. <i>Hepatology</i> , 2022, 76, 1563-1575.	3.6	45
10	Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. <i>JHEP Reports</i> , 2022, 4, 100513.	2.6	19
11	Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 2569-2580.	2.0	6
12	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , 2021, 70, 1758-1767.	6.1	51
13	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , 2021, 74, 819-828.	1.8	96
14	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. <i>United European Gastroenterology Journal</i> , 2021, 9, 427-437.	1.6	22
15	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , 2021, 15, 1160-1173.	1.9	12
16	COVID-19-Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality. <i>Hepatology Communications</i> , 2021, 5, 1660-1675.	2.0	16
17	Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 2281-2298.	1.4	1
18	Outcomes of an HCV elimination program targeting the Viennese MSM population. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 635-640.	1.0	10

#	ARTICLE	IF	CITATIONS
19	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , 2021, 41, 2159-2170.	1.9	36
20	COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. <i>PLoS ONE</i> , 2021, 16, e0256544.	1.1	16
21	Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19. <i>Journal of Personalized Medicine</i> , 2021, 11, 1264.	1.1	10
22	Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. <i>United European Gastroenterology Journal</i> , 2021, 9, 1119-1127.	1.6	20